Skip to main content

Table 4 Cost-Effectiveness of Using the Bang et al. and Kshirsagar et al. Risk Scores to Identify Persons for CKD Screening

From: The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease

Screening Scenario

Means

ICER (2016 US $ per QALY)

Lifetime Costs (2016 US $)

Lifetime QALYs

No screening

$139,200

21.349

—

Bang et al. risk score

 1-year follow-up screening

  Risk threshold = 0.20

$139,945 (134,865, 147,248)

21.366 (20.659, 21.915)

$43,791 per QALY

  Risk threshold = 0.15

$140,024 (135,020, 147,634)

21.367 (20.660, 21.903)

$79,408 per QALY

  Risk threshold = 0.10

$140,152 (135,122, 147,313)

21.370 (20.660, 21.931)

$42,645 per QALY

  Risk threshold = 0.05

$140,317 (134,909, 147,273)

21.372 (20.664, 21.919)

$82,165 per QALY

  Risk threshold = 0.02

$140,566 (133,133, 145,052)

21.374 (20.602, 21.826)

$124,626 per QALY

 2-year follow-up screening

  Risk threshold = 0.20

$139,783 (135,227, 147,465)

21.363 (20.688, 21.912)

$41,594 per QALY

  Risk threshold = 0.15

$139,820 (135,201, 147,212)

21.365 (20.664, 21.888)

$18,749 per QALY

  Risk threshold = 0.10

$139,880 (135,064, 147,565)

21.368 (20.652, 21.938)

$19,852 per QALY

  Risk threshold = 0.05

$139,939 (134,902, 147,208)

21.370 (20.655, 21.904)

$29,778 per QALY

  Risk threshold = 0.02

$139,997 (135,199, 147,283)

21.373 (20.666, 21.923)

$19,116 per QALY

 5-year follow-up screening

  Risk threshold = 0.20

$139,708 (135,002, 147,573)

21.361 (20.686, 21.898)

$42,277 per QALY

  Risk threshold = 0.15

$139,749 (135,108, 147,277)

21.363 (20.666, 21.890)

$20,403 per QALY

  Risk threshold = 0.10

$139,775 (135,303, 147,168)

21.366 (20.649, 21.925)

$8,823 per QALY

  Risk threshold = 0.05

$139,820 (134,826, 147,093)

21.368 (20.647, 21.917)

$22,609 per QALY

  Risk threshold = 0.02

$139,852 (134,968, 147,288)

21.371 (20.644, 21.924)

$10,662 per QALY

  Kshirsagar et al. risk score

   

 1-year follow-up screening

  Risk threshold = 0.20

$140,073 (135,007, 147,383)

21.366 (20.682, 21.915)

$51,316 per QALY

  Risk threshold = 0.15

$140,179 (135,241, 147,683)

21.369 (20.664, 21.901)

$35,292 per QALY

  Risk threshold = 0.10

$140,432 (135,483, 147,257)

21.371 (20.684, 21.916)

$126,832 per QALY

  Risk threshold = 0.05

$140,657 (135,057, 147,402)

21.374 (20.648, 21.939)

$74,996 per QALY

  Risk threshold = 0.02

$141,063 (135,111, 147,469)

21.375 (20.660, 21.946)

$405,861 per QALY

 2-year follow-up screening

  Risk threshold = 0.20

$139,807 (134,840, 147,579)

21.363 (20.634, 21.916)

$43,328 per QALY

  Risk threshold = 0.15

$139,848 (135,096, 147,115)

21.367 (20.658, 21.929)

$10,202 per QALY

  Risk threshold = 0.10

$139,980 (135,162, 147,227)

21.370 (20.657, 21.899)

$44,115 per QALY

  Risk threshold = 0.05

$140,022 (135,378, 147,369)

21.373 (20.708, 21.909)

$13,970 per QALY

  Risk threshold = 0.02

$140,131 (134,999, 147,385)

21.374 (20.689, 21.918)

$109,186 per QALY

 5-year follow-up screening

  Risk threshold = 0.20

$139,705 (135,092, 147,340)

21.361 (20.670, 21.893)

$42,001 per QALY

  Risk threshold = 0.15

$139,744 (135,192, 147,309)

21.365 (20.659, 21.917)

$9,926 per QALY

  Risk threshold = 0.10

$139,828 (135,188, 147,368)

21.367 (20.704, 21.887)

$41,910 per QALY

  Risk threshold = 0.05

$139,853 (134,908, 147,298)

21.371 (20.651, 21.947)

$6,342 per QALY

  Risk threshold = 0.02

$139,879 (134,675, 147,422)

21.372 (20.653, 21.925)

$25,366 per QALY

  1. CKD chronic kidney disease, ICER incremental cost-effectiveness ratio, QALYs quality adjusted life years. Notes: 95% confidence intervals are in parentheses. Costs have been rounded to the nearest dollar, and QALYS have been rounded to the nearest thousandth. The Bang et al. risk score is derived from a logistic regression to predict current CKD (stage 3+) in the NHANES population. The Kshirsagar et al. risk score is derived from a logistic regression to predict onset of CKD (stage 3+) over the 9-year study period in subsamples of ARIC and the Cardiovascular Health Study (CHS). Coefficients used to generate the risk scores are given in Table 3